These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

675 related items for PubMed ID: 16076281

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Subcellular remodeling as a viable target for the treatment of congestive heart failure.
    Dhalla NS, Dent MR, Tappia PS, Sethi R, Barta J, Goyal RK.
    J Cardiovasc Pharmacol Ther; 2006 Mar; 11(1):31-45. PubMed ID: 16703218
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Inhibiting the renin-angiotensin system in myocardial infarction and heart failure: lessons from SAVE, VALIANT and CHARM, and other clinical trials.
    Tokmakova M, Solomon SD.
    Curr Opin Cardiol; 2006 Jul; 21(4):268-72. PubMed ID: 16755193
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. The renin-angiotensin system in the heart and vascular wall: new therapeutic aspects.
    Falkenhahn M, Gohlke P, Paul M, Stoll M, Unger T.
    J Cardiovasc Pharmacol; 1994 Jul; 24 Suppl 2():S6-13. PubMed ID: 7898096
    [Abstract] [Full Text] [Related]

  • 31. New concepts in post-infarction ventricular remodeling.
    Udelson JE, Patten RD, Konstam MA.
    Rev Cardiovasc Med; 2003 Jul; 4 Suppl 3():S3-12. PubMed ID: 14564229
    [Abstract] [Full Text] [Related]

  • 32. [Renin-angiotensin system modulation: instructions for use].
    Bellis A, Rozza F, Crispo S, Trimarco B.
    G Ital Cardiol (Rome); 2008 Feb; 9(2):79-89. PubMed ID: 18383770
    [Abstract] [Full Text] [Related]

  • 33. Subcellular remodelling may induce cardiac dysfunction in congestive heart failure.
    Dhalla NS, Saini-Chohan HK, Rodriguez-Leyva D, Elimban V, Dent MR, Tappia PS.
    Cardiovasc Res; 2009 Feb 15; 81(3):429-38. PubMed ID: 18852252
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Aliskiren in combination with valsartan exerts synergistic protective effects against ventricular remodeling after myocardial infarction in mice.
    Higashikuni Y, Takaoka M, Iwata H, Tanaka K, Hirata Y, Nagai R, Sata M.
    Hypertens Res; 2012 Jan 15; 35(1):62-9. PubMed ID: 21833001
    [Abstract] [Full Text] [Related]

  • 36. How to explain the differences between renin angiotensin system modulators.
    Levy BI.
    Am J Hypertens; 2005 Sep 15; 18(9 Pt 2):134S-141S. PubMed ID: 16125050
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Angiotensin II type 1 receptor blocker attenuates exacerbated left ventricular remodeling and failure in diabetes-associated myocardial infarction.
    Matsusaka H, Kinugawa S, Ide T, Matsushima S, Shiomi T, Kubota T, Sunagawa K, Tsutsui H.
    J Cardiovasc Pharmacol; 2006 Sep 15; 48(3):95-102. PubMed ID: 17031262
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Ventricular remodeling and its prevention in the treatment of heart failure.
    Patten RD, Udelson JE, Konstam MA.
    Curr Opin Cardiol; 1998 May 15; 13(3):162-7. PubMed ID: 9649938
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 34.